Review



fourth pfizer sars cov 2 booster dose  (Pfizer Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Pfizer Inc fourth pfizer sars cov 2 booster dose
    Humoral response to the booster vaccine dose. Responses in the overall cohort (A) and within sub-cohorts defined by age (B), sex <t>(C),</t> <t>prior</t> <t>SARS-CoV-2</t> infection (D), and CMV serostatus (E). * p < .05; ** p < .01; **** p < .0001. (paired t -test or Wilcoxon signed-rank test following the Shapiro–Wilk test). (F) Partial correlations (Pearson’s r ) between SARS-CoV-2 anti-RBD IgG at T0 and T1. Residuals were derived from linear regression models adjusted for age, sex, CMV serostatus, and prior SARS-CoV-2 infection. Degrees of freedom = 41. T0 = pre-boost; T1 = post-boost.
    Fourth Pfizer Sars Cov 2 Booster Dose, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pfizer+booster+dose/pmc13134772-112-9-10?v=Pfizer+Inc
    Average 86 stars, based on 1 article reviews
    fourth pfizer sars cov 2 booster dose - by Bioz Stars, 2026-06
    86/100 stars

    Images

    1) Product Images from "Immunosenescence and cytomegalovirus-associated immune signatures on severe acute respiratory syndrome coronavirus 2 booster responses"

    Article Title: Immunosenescence and cytomegalovirus-associated immune signatures on severe acute respiratory syndrome coronavirus 2 booster responses

    Journal: The Journals of Gerontology Series A: Biological Sciences and Medical Sciences

    doi: 10.1093/gerona/glag095

    Humoral response to the booster vaccine dose. Responses in the overall cohort (A) and within sub-cohorts defined by age (B), sex (C), prior SARS-CoV-2 infection (D), and CMV serostatus (E). * p < .05; ** p < .01; **** p < .0001. (paired t -test or Wilcoxon signed-rank test following the Shapiro–Wilk test). (F) Partial correlations (Pearson’s r ) between SARS-CoV-2 anti-RBD IgG at T0 and T1. Residuals were derived from linear regression models adjusted for age, sex, CMV serostatus, and prior SARS-CoV-2 infection. Degrees of freedom = 41. T0 = pre-boost; T1 = post-boost.
    Figure Legend Snippet: Humoral response to the booster vaccine dose. Responses in the overall cohort (A) and within sub-cohorts defined by age (B), sex (C), prior SARS-CoV-2 infection (D), and CMV serostatus (E). * p < .05; ** p < .01; **** p < .0001. (paired t -test or Wilcoxon signed-rank test following the Shapiro–Wilk test). (F) Partial correlations (Pearson’s r ) between SARS-CoV-2 anti-RBD IgG at T0 and T1. Residuals were derived from linear regression models adjusted for age, sex, CMV serostatus, and prior SARS-CoV-2 infection. Degrees of freedom = 41. T0 = pre-boost; T1 = post-boost.

    Techniques Used: Infection, Derivative Assay

    CD4+ and CD8+ T-cell responses to SARS-CoV-2 in the overall cohort. (A) Cellular responses. IFNt: total IFN-γ+ cells (IFN-γ+TNF-α+/−); TNFt: total TNF-α+ cells (TNF-α+IFN-γ+/−); mono-functional cells (IFNm: IFN-γ+TNF-α−; TNFm: TNF-α+IFN-γ−); and bifunctional cells (bi: IFN-γ+TNF-α+). (B–G) CD4+ T-cell responses to SARS-CoV-2 in the overall cohort. (H–M) CD8+ T-cell responses to SARS-CoV-2 in the overall cohort. Circles denote pre-boost (T0) responses and triangles denote post-boost (T1) responses. Lines connect paired observations from the same individual. * p < .05; ** p < .01; *** p < .001 (Wilcoxon signed-rank test following the Shapiro–Wilk test).
    Figure Legend Snippet: CD4+ and CD8+ T-cell responses to SARS-CoV-2 in the overall cohort. (A) Cellular responses. IFNt: total IFN-γ+ cells (IFN-γ+TNF-α+/−); TNFt: total TNF-α+ cells (TNF-α+IFN-γ+/−); mono-functional cells (IFNm: IFN-γ+TNF-α−; TNFm: TNF-α+IFN-γ−); and bifunctional cells (bi: IFN-γ+TNF-α+). (B–G) CD4+ T-cell responses to SARS-CoV-2 in the overall cohort. (H–M) CD8+ T-cell responses to SARS-CoV-2 in the overall cohort. Circles denote pre-boost (T0) responses and triangles denote post-boost (T1) responses. Lines connect paired observations from the same individual. * p < .05; ** p < .01; *** p < .001 (Wilcoxon signed-rank test following the Shapiro–Wilk test).

    Techniques Used: Functional Assay

    Effect of covariates on CD4+ T-cell cytokine outputs following ANCOVA. (A) Effect of sex and prior SARS-CoV-2 infection (COVID) on changes (Δ) in CD4+ IFNt and IFNm responses. (B) Effect of sex and age on CD4+ T-cell responses after the booster (T1), including cytokine percentages and their iMFI. For each cytokine output, symbols represent estimated marginal means for the sub-cohort groups, with 95% confidence intervals (CIs) shown as horizontal lines. p -values in the embedded table indicate the effect of each covariate on cytokine outputs and were obtained from Type III ANOVA (sums of squares). ns = not significant ( p > .05).
    Figure Legend Snippet: Effect of covariates on CD4+ T-cell cytokine outputs following ANCOVA. (A) Effect of sex and prior SARS-CoV-2 infection (COVID) on changes (Δ) in CD4+ IFNt and IFNm responses. (B) Effect of sex and age on CD4+ T-cell responses after the booster (T1), including cytokine percentages and their iMFI. For each cytokine output, symbols represent estimated marginal means for the sub-cohort groups, with 95% confidence intervals (CIs) shown as horizontal lines. p -values in the embedded table indicate the effect of each covariate on cytokine outputs and were obtained from Type III ANOVA (sums of squares). ns = not significant ( p > .05).

    Techniques Used: Infection



    Similar Products

    fourth pfizer sars cov 2 booster dose  (Pfizer Inc)
    86
    Pfizer Inc fourth pfizer sars cov 2 booster dose
    Humoral response to the booster vaccine dose. Responses in the overall cohort (A) and within sub-cohorts defined by age (B), sex <t>(C),</t> <t>prior</t> <t>SARS-CoV-2</t> infection (D), and CMV serostatus (E). * p < .05; ** p < .01; **** p < .0001. (paired t -test or Wilcoxon signed-rank test following the Shapiro–Wilk test). (F) Partial correlations (Pearson’s r ) between SARS-CoV-2 anti-RBD IgG at T0 and T1. Residuals were derived from linear regression models adjusted for age, sex, CMV serostatus, and prior SARS-CoV-2 infection. Degrees of freedom = 41. T0 = pre-boost; T1 = post-boost.
    Fourth Pfizer Sars Cov 2 Booster Dose, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pfizer+booster+dose/pmc13134772-112-9-10?v=Pfizer+Inc
    Average 86 stars, based on 1 article reviews
    fourth pfizer sars cov 2 booster dose - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    pfizer booster dose  (Pfizer Inc)
    86
    Pfizer Inc pfizer booster dose
    Humoral response to the booster vaccine dose. Responses in the overall cohort (A) and within sub-cohorts defined by age (B), sex <t>(C),</t> <t>prior</t> <t>SARS-CoV-2</t> infection (D), and CMV serostatus (E). * p < .05; ** p < .01; **** p < .0001. (paired t -test or Wilcoxon signed-rank test following the Shapiro–Wilk test). (F) Partial correlations (Pearson’s r ) between SARS-CoV-2 anti-RBD IgG at T0 and T1. Residuals were derived from linear regression models adjusted for age, sex, CMV serostatus, and prior SARS-CoV-2 infection. Degrees of freedom = 41. T0 = pre-boost; T1 = post-boost.
    Pfizer Booster Dose, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pfizer+booster+dose/pmc12656545-102-6-6?v=Pfizer+Inc
    Average 86 stars, based on 1 article reviews
    pfizer booster dose - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    covid-19 booster doses of pfizer ba.4/5  (Pfizer Inc)
    90
    Pfizer Inc covid-19 booster doses of pfizer ba.4/5
    Humoral response to the booster vaccine dose. Responses in the overall cohort (A) and within sub-cohorts defined by age (B), sex <t>(C),</t> <t>prior</t> <t>SARS-CoV-2</t> infection (D), and CMV serostatus (E). * p < .05; ** p < .01; **** p < .0001. (paired t -test or Wilcoxon signed-rank test following the Shapiro–Wilk test). (F) Partial correlations (Pearson’s r ) between SARS-CoV-2 anti-RBD IgG at T0 and T1. Residuals were derived from linear regression models adjusted for age, sex, CMV serostatus, and prior SARS-CoV-2 infection. Degrees of freedom = 41. T0 = pre-boost; T1 = post-boost.
    Covid 19 Booster Doses Of Pfizer Ba.4/5, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pfizer+booster+dose/pmc11700711-86-13-13?v=Pfizer+Inc
    Average 90 stars, based on 1 article reviews
    covid-19 booster doses of pfizer ba.4/5 - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier
    booster doses pfizer  (Pfizer Inc)
    90
    Pfizer Inc booster doses pfizer
    Humoral response to the booster vaccine dose. Responses in the overall cohort (A) and within sub-cohorts defined by age (B), sex <t>(C),</t> <t>prior</t> <t>SARS-CoV-2</t> infection (D), and CMV serostatus (E). * p < .05; ** p < .01; **** p < .0001. (paired t -test or Wilcoxon signed-rank test following the Shapiro–Wilk test). (F) Partial correlations (Pearson’s r ) between SARS-CoV-2 anti-RBD IgG at T0 and T1. Residuals were derived from linear regression models adjusted for age, sex, CMV serostatus, and prior SARS-CoV-2 infection. Degrees of freedom = 41. T0 = pre-boost; T1 = post-boost.
    Booster Doses Pfizer, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pfizer+booster+dose/pmc11598339-76-33-36?v=Pfizer+Inc
    Average 90 stars, based on 1 article reviews
    booster doses pfizer - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Humoral response to the booster vaccine dose. Responses in the overall cohort (A) and within sub-cohorts defined by age (B), sex (C), prior SARS-CoV-2 infection (D), and CMV serostatus (E). * p < .05; ** p < .01; **** p < .0001. (paired t -test or Wilcoxon signed-rank test following the Shapiro–Wilk test). (F) Partial correlations (Pearson’s r ) between SARS-CoV-2 anti-RBD IgG at T0 and T1. Residuals were derived from linear regression models adjusted for age, sex, CMV serostatus, and prior SARS-CoV-2 infection. Degrees of freedom = 41. T0 = pre-boost; T1 = post-boost.

    Journal: The Journals of Gerontology Series A: Biological Sciences and Medical Sciences

    Article Title: Immunosenescence and cytomegalovirus-associated immune signatures on severe acute respiratory syndrome coronavirus 2 booster responses

    doi: 10.1093/gerona/glag095

    Figure Lengend Snippet: Humoral response to the booster vaccine dose. Responses in the overall cohort (A) and within sub-cohorts defined by age (B), sex (C), prior SARS-CoV-2 infection (D), and CMV serostatus (E). * p < .05; ** p < .01; **** p < .0001. (paired t -test or Wilcoxon signed-rank test following the Shapiro–Wilk test). (F) Partial correlations (Pearson’s r ) between SARS-CoV-2 anti-RBD IgG at T0 and T1. Residuals were derived from linear regression models adjusted for age, sex, CMV serostatus, and prior SARS-CoV-2 infection. Degrees of freedom = 41. T0 = pre-boost; T1 = post-boost.

    Article Snippet: In this study, we evaluated the effect of a fourth Pfizer SARS-CoV-2 booster dose on humoral and cellular immune responses in a healthy population, considering age, sex, prior SARS-CoV-2 infection, and CMV serostatus, and the impact of immunosenescence.

    Techniques: Infection, Derivative Assay

    CD4+ and CD8+ T-cell responses to SARS-CoV-2 in the overall cohort. (A) Cellular responses. IFNt: total IFN-γ+ cells (IFN-γ+TNF-α+/−); TNFt: total TNF-α+ cells (TNF-α+IFN-γ+/−); mono-functional cells (IFNm: IFN-γ+TNF-α−; TNFm: TNF-α+IFN-γ−); and bifunctional cells (bi: IFN-γ+TNF-α+). (B–G) CD4+ T-cell responses to SARS-CoV-2 in the overall cohort. (H–M) CD8+ T-cell responses to SARS-CoV-2 in the overall cohort. Circles denote pre-boost (T0) responses and triangles denote post-boost (T1) responses. Lines connect paired observations from the same individual. * p < .05; ** p < .01; *** p < .001 (Wilcoxon signed-rank test following the Shapiro–Wilk test).

    Journal: The Journals of Gerontology Series A: Biological Sciences and Medical Sciences

    Article Title: Immunosenescence and cytomegalovirus-associated immune signatures on severe acute respiratory syndrome coronavirus 2 booster responses

    doi: 10.1093/gerona/glag095

    Figure Lengend Snippet: CD4+ and CD8+ T-cell responses to SARS-CoV-2 in the overall cohort. (A) Cellular responses. IFNt: total IFN-γ+ cells (IFN-γ+TNF-α+/−); TNFt: total TNF-α+ cells (TNF-α+IFN-γ+/−); mono-functional cells (IFNm: IFN-γ+TNF-α−; TNFm: TNF-α+IFN-γ−); and bifunctional cells (bi: IFN-γ+TNF-α+). (B–G) CD4+ T-cell responses to SARS-CoV-2 in the overall cohort. (H–M) CD8+ T-cell responses to SARS-CoV-2 in the overall cohort. Circles denote pre-boost (T0) responses and triangles denote post-boost (T1) responses. Lines connect paired observations from the same individual. * p < .05; ** p < .01; *** p < .001 (Wilcoxon signed-rank test following the Shapiro–Wilk test).

    Article Snippet: In this study, we evaluated the effect of a fourth Pfizer SARS-CoV-2 booster dose on humoral and cellular immune responses in a healthy population, considering age, sex, prior SARS-CoV-2 infection, and CMV serostatus, and the impact of immunosenescence.

    Techniques: Functional Assay

    Effect of covariates on CD4+ T-cell cytokine outputs following ANCOVA. (A) Effect of sex and prior SARS-CoV-2 infection (COVID) on changes (Δ) in CD4+ IFNt and IFNm responses. (B) Effect of sex and age on CD4+ T-cell responses after the booster (T1), including cytokine percentages and their iMFI. For each cytokine output, symbols represent estimated marginal means for the sub-cohort groups, with 95% confidence intervals (CIs) shown as horizontal lines. p -values in the embedded table indicate the effect of each covariate on cytokine outputs and were obtained from Type III ANOVA (sums of squares). ns = not significant ( p > .05).

    Journal: The Journals of Gerontology Series A: Biological Sciences and Medical Sciences

    Article Title: Immunosenescence and cytomegalovirus-associated immune signatures on severe acute respiratory syndrome coronavirus 2 booster responses

    doi: 10.1093/gerona/glag095

    Figure Lengend Snippet: Effect of covariates on CD4+ T-cell cytokine outputs following ANCOVA. (A) Effect of sex and prior SARS-CoV-2 infection (COVID) on changes (Δ) in CD4+ IFNt and IFNm responses. (B) Effect of sex and age on CD4+ T-cell responses after the booster (T1), including cytokine percentages and their iMFI. For each cytokine output, symbols represent estimated marginal means for the sub-cohort groups, with 95% confidence intervals (CIs) shown as horizontal lines. p -values in the embedded table indicate the effect of each covariate on cytokine outputs and were obtained from Type III ANOVA (sums of squares). ns = not significant ( p > .05).

    Article Snippet: In this study, we evaluated the effect of a fourth Pfizer SARS-CoV-2 booster dose on humoral and cellular immune responses in a healthy population, considering age, sex, prior SARS-CoV-2 infection, and CMV serostatus, and the impact of immunosenescence.

    Techniques: Infection